Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03573505
Registration number
NCT03573505
Ethics application status
Date submitted
19/06/2018
Date registered
29/06/2018
Date last updated
11/12/2020
Titles & IDs
Public title
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
Query!
Scientific title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis
Query!
Secondary ID [1]
0
0
2017-003158-18
Query!
Secondary ID [2]
0
0
203PF203
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SPIRIT
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Connective tissue diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BG00011
Treatment: Drugs - Placebo
Experimental: BG00011 - Participants will receive BG00011 56 mg once weekly by subcutaneous (SC) injection for 52 weeks.
Placebo comparator: Placebo - Participants will receive placebo once weekly by (SC) injection for 52 weeks.
Treatment: Drugs: BG00011
Administered as specified in the treatment arm.
Treatment: Drugs: Placebo
Administered as specified in the treatment arm.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline in Forced (Expiratory) Vital Capacity (FVC) at Week 52
Query!
Assessment method [1]
0
0
FVC is the total amount of air exhaled during the forced expiratory volume test that is measured during spirometry and is the most important measurement of lung function. This test requires participant to breath into a tube connected to a machine that measures the amount of air that can be moved in and out of the lungs. Change from baseline is defined as post-baseline value minus baseline value. A negative change from baseline indicates decline.
Query!
Timepoint [1]
0
0
Baseline, Week 52
Query!
Secondary outcome [1]
0
0
Change From Baseline in FVC, Expressed in Percent Predicted at Week 52
Query!
Assessment method [1]
0
0
FVC is the total amount of air exhaled during the forced expiratory volume test that is measured during spirometry and is the most important measurement of lung function. This test requires participant to breath into a tube connected to a machine that measures the amount of air that can be moved in and out of the lungs after taking an inhaled bronchodilator medicine which is used to dilate participant's bronchial (breathing) tubes. Percent predicted FVC (in %, here FVC was measured in litres) = \[(observed FVC)/(predicted FVC)\]\*100. Change from baseline is defined as post-baseline value minus baseline value. A negative change from baseline indicates decline.
Query!
Timepoint [1]
0
0
Baseline, Week 52
Query!
Secondary outcome [2]
0
0
Time to Progression
Query!
Assessment method [2]
0
0
Time to progression is defined by a composite endpoint, including any of the following events: Absolute decline of 10% predicted in FVC (FVC percent predicted (baseline) - FVC percent predicted (progression) =10%); Non-elective hospitalization for respiratory events; Lung transplantation or death. The earliest time to meet at least 1 composite criterion was calculated.
Query!
Timepoint [2]
0
0
Up to Week 60 (End of Study)
Query!
Secondary outcome [3]
0
0
Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation
Query!
Assessment method [3]
0
0
Time to first acute IPF exacerbation is defined as time from randomization to the first occurrence of acute IPF exacerbation. Acute IPF exacerbation is defined as a clinically significant deterioration of unidentifiable cause in a participant with underlying IPF. The diagnostic criteria for IPF used in this study were derived from evidence-based guidelines developed by the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association (ATS/ERS/JRS/ALAT) joint task force for the diagnosis and management of IPF. Participants were assessed according to the modified 2007 diagnostic criteria for acute IPF exacerbation.
Query!
Timepoint [3]
0
0
Up to Early Termination Visit (Up to Week 52)
Query!
Secondary outcome [4]
0
0
Number of Participants With at Least One Acute IPF Exacerbation
Query!
Assessment method [4]
0
0
Acute IPF exacerbation is defined as a clinically significant deterioration of unidentifiable cause in a participant with underlying IPF. The diagnostic criteria for IPF used in this study were derived from evidence-based guidelines developed by the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association (ATS/ERS/JRS/ALAT) joint task force for the diagnosis and management of IPF. Participants were assessed according to the modified 2007 diagnostic criteria for acute IPF exacerbation.
Query!
Timepoint [4]
0
0
Up to Early Termination Visit (Up to Week 52)
Query!
Secondary outcome [5]
0
0
Number of IPF Exacerbations
Query!
Assessment method [5]
0
0
The IPF exacerbation is defined as a clinically significant deterioration of unidentifiable cause in a participant with underlying IPF. The diagnostic criteria for IPF used in this study were derived from evidence-based guidelines developed by the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association (ATS/ERS/JRS/ALAT) joint task force for the diagnosis and management of IPF. Participants were assessed according to the modified 2007 diagnostic criteria for acute IPF exacerbation.
Query!
Timepoint [5]
0
0
Up to Early Termination Visit (Up to Week 52)
Query!
Secondary outcome [6]
0
0
Number of Participants With Absolute Decline of 10% Predicted in FVC
Query!
Assessment method [6]
0
0
FVC is the is the total amount of air exhaled during the forced expiratory volume test that is measured during spirometry and is the most important measurement of lung function. This test requires participant to breath into a tube connected to a machine that measures the amount of air that can be moved in and out of the lungs after taking an inhaled bronchodilator medicine which is used to dilate participant's bronchial (breathing) tubes. Absolute Decline of 10% = FVC percent predicted (baseline) - FVC percent predicted (progression) =10%.
Query!
Timepoint [6]
0
0
Up to Early Termination Visit (Up to Week 52)
Query!
Secondary outcome [7]
0
0
Time to Death or Lung Transplantation
Query!
Assessment method [7]
0
0
Time to Death or Lung Transplantation is defined as the time from randomization to the first occurrence of any one of the event (death or lung transplantation).
Query!
Timepoint [7]
0
0
Up to Week 60 (End of Study)
Query!
Secondary outcome [8]
0
0
Time to All Non-elective Hospitalizations
Query!
Assessment method [8]
0
0
Time to all non-elective hospitalizations is defined as the time from randomization to the first occurrence of hospitalization which was not elected by the participant.
Query!
Timepoint [8]
0
0
Up to Week 60 (End of Study)
Query!
Secondary outcome [9]
0
0
Time to All Non-Elective Respiratory Hospitalizations
Query!
Assessment method [9]
0
0
Time to all non-elective respiratory hospitalizations is defined as the time from randomization to the first occurrence of hospitalization due to respiratory problems, which was not elected by the participant.
Query!
Timepoint [9]
0
0
Up to Week 60 (End of Study)
Query!
Secondary outcome [10]
0
0
Change From Baseline in Absolute FVC
Query!
Assessment method [10]
0
0
FVC is the total amount of air exhaled during the forced expiratory volume test that is measured during spirometry and is the most important measurement of lung function. This test requires participant to breath into a tube connected to a machine that measures the amount of air that can be moved in and out of the lungs after taking an inhaled bronchodilator medicine which is used to dilate participant's bronchial (breathing) tubes. Change from baseline is defined as post-baseline value minus baseline value. A negative change from baseline indicates decline.
Query!
Timepoint [10]
0
0
Up to Week 44
Query!
Secondary outcome [11]
0
0
Change From Baseline in Percent Predicted FVC
Query!
Assessment method [11]
0
0
FVC is the total amount of air exhaled during the forced expiratory volume test that is measured during spirometry and is the most important measurement of lung function. This test requires participant to breath into a tube connected to a machine that measures the amount of air that can be moved in and out of the lungs after taking an inhaled bronchodilator medicine which is used to dilate participant's bronchial (breathing) tubes. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100. Change from baseline is defined as post-baseline value minus baseline value. A negative change from baseline indicates decline.
Query!
Timepoint [11]
0
0
Up to Week 44
Query!
Secondary outcome [12]
0
0
Change From Baseline in Absolute Carbon Monoxide Diffusion Capacity (DLco)
Query!
Assessment method [12]
0
0
DLCO is a measurement of the ability of the lungs to transfer gases from the air to the blood. Evaluation of DLco was be performed by single-breath carbon monoxide diffusing capacity. DLCO was assessed in milliliters per minute per millimeter of mercury (mL/min/mmHg). Change from baseline is defined as post-baseline value minus baseline value. A negative change from baseline indicates decline.
Query!
Timepoint [12]
0
0
Up to Early Termination Visit (Up to Week 52)
Query!
Secondary outcome [13]
0
0
Change From Baseline in Percent Predicted Carbon Monoxide Diffusion Capacity (DLco)
Query!
Assessment method [13]
0
0
DLCO is a measurement of the ability of the lungs to transfer gases from the air to the blood. Evaluation of DLco was be performed by single-breath carbon monoxide diffusing capacity. Percent of predicted DLco (in %) = \[(observed DLco)/(predicted DLco)\]\*100. Change from baseline is defined as post-baseline value minus baseline value. A negative change from baseline indicates decline.
Query!
Timepoint [13]
0
0
Up to Early Termination Visit (Up to Week 52)
Query!
Secondary outcome [14]
0
0
Change From Baseline in Absolute Total Lung Capacity (TLC)
Query!
Assessment method [14]
0
0
Total lung capacity is the measure of lung volume was measured by full-body plethysmography. Change from baseline is defined as post-baseline value minus baseline value. A negative change from baseline indicates decline.
Query!
Timepoint [14]
0
0
Up to Early Termination Visit (Up to Week 52)
Query!
Secondary outcome [15]
0
0
Change From Baseline in Percent Predicted TLC
Query!
Assessment method [15]
0
0
Total lung capacity is the measure of lung volume was measured by full-body plethysmography. Percent predicted TLC (in %) = \[(observed TLC)/(predicted TLC)\]\*100. Change from baseline is defined as post-baseline value minus baseline value. A negative change from baseline indicates decline.
Query!
Timepoint [15]
0
0
Up to Early Termination Visit (Up to Week 52)
Query!
Secondary outcome [16]
0
0
Change From Baseline in 6 Minute Walk Test (6MWT) Parameters
Query!
Assessment method [16]
0
0
The 6MWT measures the distance (in meters), a participant is able to walk in 6 minutes. This test measures the distance a person can walk quickly on a flat, hard surface in 6 minutes and reflects an individual's ability to perform daily physical activities.
Query!
Timepoint [16]
0
0
Baseline, Week 26 and Week 52
Query!
Secondary outcome [17]
0
0
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [17]
0
0
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death, requires inpatient hospitalization, results in persistent or significant disability and/or results in a congenital anomaly.
Query!
Timepoint [17]
0
0
Up to Week 60 (End of Study)
Query!
Secondary outcome [18]
0
0
Number of Participants With Anti-BG00011 Antibodies in the Serum
Query!
Assessment method [18]
0
0
Query!
Timepoint [18]
0
0
Up to Week 60 (End of Study)
Query!
Secondary outcome [19]
0
0
Concentration of BG00011 in the Serum
Query!
Assessment method [19]
0
0
Query!
Timepoint [19]
0
0
Predose on Day 0, Day 5, Week 4, Week 8, Week 12, Week 26, Week 38, Week 52, and Safety Follow-up Visit (Up to Week 60)
Query!
Eligibility
Key inclusion criteria
Key
* Female subjects must be surgically sterile, postmenopausal (minimum 1 year without menses), or agree to use 1 or more forms of highly effective contraception from the time of signing of the informed consent form (ICF) until 3 months after the last injection of study medication. Male subjects must also agree to use 1 or more forms of highly effective contraception for either themselves or their partners from signing of ICF until 4 months after last injection of study medication.
* IPF diagnosed based on modified ATS/ERS/JRS/ALAT IPF guideline for diagnosis and management, within 3 years of Screening.
* Combination of high-resolution computed tomography (HRCT) pattern and, if one has been obtained, surgical lung biopsy pattern, consistent with diagnosis of IPF.
* Carbon monoxide diffusion capacity (DLco) (corrected for hemoglobin): 30% to 79% predicted of normal at Screening, with no clinically significant deterioration between the Screening Visit and randomization, as determined by the Investigator.
* Forced (expiratory) vital capacity (FVC) =50% predicted of normal at Screening, with no clinically significant deterioration between the Screening Visit and randomization, as determined by the Investigator.
* If a subject is taking nintedanib or pirfenidone, they must be on a stable dose for at least 8 weeks prior to randomization.
Key
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Unable to perform pulmonary functional tests (PFTs) or undergo HRCT procedure.
* Peripheral capillary oxygen saturation (SpO2) <90% at rest (if on oxygen supplementation, must be =2 L/min at rest).
* Airway obstruction (i.e., prebronchodilator FEV1/FVC <0.7) or evidence of a bronchodilator response as defined by an absolute increase of =12% and an increase of =200 milliliters (mL) in FEV1 or FVC, or both, after bronchodilator use, compared with the values before bronchodilator use at Screening.
* End-stage fibrotic disease likely requiring organ transplantation within 12 months, or if the subject has initiated active evaluation for organ transplantation.
* The extent of emphysema in the lungs exceeds fibrosis, based on central review of HRCT scans.
* Body weight <60 kg at Screening.
* History of or ongoing malignant disease, including solid tumors and hematologic malignancies, with the exception of basal cell carcinomas, squamous cell carcinomas, and carcinoma in situ of the cervix that have been completely excised and considered cured >2 years prior to Screening.
* Significant cardiac disease (e.g., New York Heart Association Class 3 or 4; myocardial infarction within the past 6 months; unstable angina; coronary angioplasty or coronary artery bypass graft within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias; or pulmonary hypertension requiring pharmacologic treatment).
* Clinical diagnosis of any connective tissue disease (including but not limited to scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus, and rheumatoid arthritis) or a diagnosis of interstitial pneumonia with autoimmune features as determined by the Investigator.
* Other disease that may interfere with testing procedures or, in the judgment of the Investigator, may interfere with study participation or may put the patient at risk when participating in this study.
* Other unspecified reasons that, in the opinion of the Investigator or Biogen, make the subject unsuitable for enrollment.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
24/09/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
14/11/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
109
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Research Site - Darlinghurst
Query!
Recruitment hospital [2]
0
0
Research Site - New Lambton Heights
Query!
Recruitment hospital [3]
0
0
Research Site - Newtown
Query!
Recruitment hospital [4]
0
0
Research Site - Chermside
Query!
Recruitment hospital [5]
0
0
Research Site - Nundah
Query!
Recruitment hospital [6]
0
0
Research Site - Woolloongabba
Query!
Recruitment hospital [7]
0
0
Research Site - Frankston
Query!
Recruitment hospital [8]
0
0
Research Site - Melbourne
Query!
Recruitment hospital [9]
0
0
Research Site - Murdoch
Query!
Recruitment hospital [10]
0
0
Research Site - Heidelberg
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
2305 - New Lambton Heights
Query!
Recruitment postcode(s) [3]
0
0
2042 - Newtown
Query!
Recruitment postcode(s) [4]
0
0
4032 - Chermside
Query!
Recruitment postcode(s) [5]
0
0
4012 - Nundah
Query!
Recruitment postcode(s) [6]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [7]
0
0
3939 - Frankston
Query!
Recruitment postcode(s) [8]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [9]
0
0
6150 - Murdoch
Query!
Recruitment postcode(s) [10]
0
0
3084 - Heidelberg
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Iowa
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Minnesota
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Missouri
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New Hampshire
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Ohio
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Pennsylvania
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Rhode Island
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
South Carolina
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Tennessee
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Texas
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Virginia
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Washington
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Wisconsin
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Buenos Aires
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Tucuman
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Bruxelles
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Leuven
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Yvoir
Query!
Country [27]
0
0
Chile
Query!
State/province [27]
0
0
Talca
Query!
Country [28]
0
0
Czechia
Query!
State/province [28]
0
0
Olomouc
Query!
Country [29]
0
0
Czechia
Query!
State/province [29]
0
0
Plzen Bory
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Praha 4
Query!
Country [31]
0
0
Czechia
Query!
State/province [31]
0
0
Praha 8
Query!
Country [32]
0
0
Denmark
Query!
State/province [32]
0
0
Aarhus C
Query!
Country [33]
0
0
Denmark
Query!
State/province [33]
0
0
Hellerup
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Herault
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Ille Et Vilaine
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Paris
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Rhone
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Seine Saint Denis
Query!
Country [39]
0
0
Greece
Query!
State/province [39]
0
0
Heraklion
Query!
Country [40]
0
0
Greece
Query!
State/province [40]
0
0
Larissa
Query!
Country [41]
0
0
Israel
Query!
State/province [41]
0
0
Haifa
Query!
Country [42]
0
0
Israel
Query!
State/province [42]
0
0
Jerusalem
Query!
Country [43]
0
0
Israel
Query!
State/province [43]
0
0
Kfar-Saba
Query!
Country [44]
0
0
Israel
Query!
State/province [44]
0
0
Petach Tikva
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Cesena
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Catania
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Milano
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Roma
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Siena
Query!
Country [50]
0
0
Korea, Republic of
Query!
State/province [50]
0
0
Gyeonggi-do
Query!
Country [51]
0
0
Korea, Republic of
Query!
State/province [51]
0
0
Seoul
Query!
Country [52]
0
0
Netherlands
Query!
State/province [52]
0
0
Amsterdam
Query!
Country [53]
0
0
Netherlands
Query!
State/province [53]
0
0
Nieuwegein
Query!
Country [54]
0
0
Netherlands
Query!
State/province [54]
0
0
Rotterdam
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Gdansk
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Warszawa
Query!
Country [57]
0
0
Russian Federation
Query!
State/province [57]
0
0
Ekaterinburg
Query!
Country [58]
0
0
Russian Federation
Query!
State/province [58]
0
0
Kazan
Query!
Country [59]
0
0
Russian Federation
Query!
State/province [59]
0
0
Saint-Petersburg
Query!
Country [60]
0
0
Russian Federation
Query!
State/province [60]
0
0
Yaroslavl
Query!
Country [61]
0
0
Spain
Query!
State/province [61]
0
0
Barcelona
Query!
Country [62]
0
0
Spain
Query!
State/province [62]
0
0
Madrid
Query!
Country [63]
0
0
Spain
Query!
State/province [63]
0
0
Sevilla
Query!
Country [64]
0
0
Spain
Query!
State/province [64]
0
0
Valencia
Query!
Country [65]
0
0
United Kingdom
Query!
State/province [65]
0
0
Cambridgeshire
Query!
Country [66]
0
0
United Kingdom
Query!
State/province [66]
0
0
Devon
Query!
Country [67]
0
0
United Kingdom
Query!
State/province [67]
0
0
Greater London
Query!
Country [68]
0
0
United Kingdom
Query!
State/province [68]
0
0
Lothian Region
Query!
Country [69]
0
0
United Kingdom
Query!
State/province [69]
0
0
Merseyside
Query!
Country [70]
0
0
United Kingdom
Query!
State/province [70]
0
0
Tyne & Wear
Query!
Country [71]
0
0
United Kingdom
Query!
State/province [71]
0
0
West Yorkshire
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Biogen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is to evaluate the efficacy of BG00011 compared with placebo in participants with Idiopathic Pulmonary Fibrosis (IPF). The secondary objectives of this study are: to evaluate the efficacy of BG00011 compared with placebo in participants with IPF as determined by change in percent predicted forced (expiratory) vital capacity (FVC); to assess progression-free survival in participants who receive BG00011 compared with placebo; to assess the occurrence of IPF exacerbation in participants who receive BG00011 compared with placebo; to assess the incidence of absolute decline in FVC =10% in participants who receive BG00011 compared with placebo; to assess the time to death or lung transplantation in participants who receive BG00011 compared with placebo, and the transplant-free survival rate at Week 26 and Week 52; to assess the time to non-elective hospitalizations in participants who receive BG00011 compared with placebo; to assess additional pulmonary function test (PFT) findings in participants who receive BG00011 compared with placebo; To assess performance on the 6 minute walk test (6MWT) in participants who receive BG00011 compared with placebo; to evaluate the safety and tolerability of BG00011; and to evaluate the serum concentration of BG00011.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03573505
Query!
Trial related presentations / publications
Raghu G, Mouded M, Chambers DC, Martinez FJ, Richeldi L, Lancaster LH, Hamblin MJ, Gibson KF, Rosas IO, Prasse A, Zhao G, Serenko M, Novikov N, McCurley A, Bansal P, Stebbins C, Arefayene M, Ibebunjo S, Violette SM, Gallagher D, Behr J. A Phase IIb Randomized Clinical Study of an Anti-alphavbeta6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022 Nov 1;206(9):1128-1139. doi: 10.1164/rccm.202112-2824OC. Shenderov K, Collins SL, Powell JD, Horton MR. Immune dysregulation as a driver of idiopathic pulmonary fibrosis. J Clin Invest. 2021 Jan 19;131(2):e143226. doi: 10.1172/JCI143226.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Biogen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/05/NCT03573505/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/05/NCT03573505/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT03573505
Download to PDF